Healthcare / Drug Manufacturers - GeneralKOSDAQ
$3750.00
-20.00 (-0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $1.6B · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$38.3B
P/E
N/A
•EV/EBITDA
11.6x
↓ROE
-6.9%
↓Gross Margin
40.4%
↓Debt/Equity
1.22
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
+52.4%
FCF margin
2.1%
FCF / Net income
-0.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $75.80B · net income $-4.90B · FCF $1.57B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $75.80B | $75.80B | $74.81B | $75.11B | $72.70B |
| Net Income | $-4.90B | $-4.90B | $-4.43B | $2.63B | $281.3M |
| EBITDA | $9.98B | $9.98B | $9.69B | $13.91B | $9.48B |
| EPS | -527.00 | -527.00 | -434.55 | 257.85 | 27.27 |
| Gross Margin | 40.4% | 40.4% | 37.5% | 42.6% | 37.7% |
| Operating Margin | 2.6% | 2.6% | 2.0% | 8.5% | 2.6% |
| Net Margin | -6.5% | -6.5% | -5.9% | 3.5% | 0.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.22 | 1.22 | 1.16 | 1.12 | 1.18 |
| Current Ratio | 2.36 | 2.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.57B | $1.57B | $1.63B | $8.23B | $444.4M |
| Returns | |||||
| ROE | -6.9% | -6.9% | -5.8% | 3.2% | 0.4% |
| Valuation | |||||
| P/E | — | — | — | 21.38 | 253.03 |
| EV/EBITDA | 11.64 | 11.64 | 13.14 | 10.15 | 17.03 |
| P/B | 0.49 | 0.49 | 0.57 | 0.69 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | 1.3% | 1.3% | -0.4% | 3.3% | — |
| EPS Growth | -21.3% | -21.3% | -268.5% | 845.5% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-434.55 → -527.00
Residual
-13.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.